First Time Loading...

Y-mAbs Therapeutics Inc
NASDAQ:YMAB

Watchlist Manager
Y-mAbs Therapeutics Inc Logo
Y-mAbs Therapeutics Inc
NASDAQ:YMAB
Watchlist
Price: 14.71 USD -0.88% Market Closed
Updated: Apr 27, 2024

Y-mAbs Therapeutics Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Y-mAbs Therapeutics Inc
Operating Income Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Y-mAbs Therapeutics Inc
NASDAQ:YMAB
Operating Income
-$21.2m
CAGR 3-Years
44%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Operating Income
$16.6B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$9.3B
CAGR 3-Years
32%
CAGR 5-Years
2%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Operating Income
$8.2B
CAGR 3-Years
-4%
CAGR 5-Years
-5%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$3.8B
CAGR 3-Years
10%
CAGR 5-Years
42%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$4.2B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
19%

See Also

What is Y-mAbs Therapeutics Inc's Operating Income?
Operating Income
-21.2m USD

Based on the financial report for Dec 31, 2023, Y-mAbs Therapeutics Inc's Operating Income amounts to -21.2m USD.

What is Y-mAbs Therapeutics Inc's Operating Income growth rate?
Operating Income CAGR 5Y
13%

Over the last year, the Operating Income growth was 78%. The average annual Operating Income growth rates for Y-mAbs Therapeutics Inc have been 44% over the past three years , 13% over the past five years .